Elizabeth B Pitchford, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 11588 Pulaski Pike, Toney, AL 35773 Phone: 256-693-1006 Fax: 256-428-7561 |
News Archive
When exposed in a laboratory to pollution levels comparable to those found in the atmosphere of the Amazon region during the forest and crop burning season, human lung cells suffer severe DNA damage and stop dividing. After 72 hours of exposure, over 30% of the cultured cells are dead.
ARIAD Pharmaceuticals, Inc. today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL.
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
A new universal test to predict the risk of someone succumbing to major depression has been developed by UCL (University College London) researchers. The online tool, predictD, could eventually be used by family doctors and local clinics to identify those at risk of depression for whom prevention might be most useful.
› Verified 5 days ago